Patents Assigned to Urocor, Inc.
-
Patent number: 7332270Abstract: Disclosed are diagnostic techniques for the detection of human disease states that affect gene expression in peripheral leukocytes. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. The invention further relates to methods for detection of protein species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. Genetic probes, antibody probes and methods useful in monitoring the progression and diagnosis of two specific disease states, prostatic cancer and breast cancer, are described.Type: GrantFiled: September 11, 2000Date of Patent: February 19, 2008Assignee: Urocor, Inc.Inventors: David Ralph, Gang An, S. Mark O'Hara, Robert Veltri
-
Publication number: 20030050470Abstract: Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue.Type: ApplicationFiled: October 10, 2001Publication date: March 13, 2003Applicant: UroCor, Inc.Inventors: Gang An, S. Mark O'Hara, David Ralph, Robert Veltri
-
Publication number: 20030017472Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.Type: ApplicationFiled: September 25, 2001Publication date: January 23, 2003Applicant: UROCOR, INC.Inventors: Gang An, Robert Veltri
-
Patent number: 6463438Abstract: A neural network is used in a system to detect abnormalities in cells, including cancer in bladder tissue cells. The system has an image analysis system for generating data representative of imaging variables from an image of stained cells. The set of data is provided to a neural network which has been trained to detect abnormalities from known tissue cells with respect to the data from the same set of imaging variables. A conventional sigmoid-activated neural network, or alternatively, a hybrid neural network having a combination of sigmoid, gaussian and sinusoidal activation functions may be utilized. The trained neural network applies a set of weight factors obtained during training to the data to classify the unknown tissue cell as normal or abnormal.Type: GrantFiled: June 3, 1994Date of Patent: October 8, 2002Assignee: Urocor, Inc.Inventors: Robert W. Veltri, Kaveh Ashenayi, Ying Hu, Gerard J. O'Dowd
-
Publication number: 20020068281Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.Type: ApplicationFiled: January 2, 2001Publication date: June 6, 2002Applicant: UROCOR, INC.Inventors: Gang An, Robert Veltri
-
Patent number: 6369195Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.Type: GrantFiled: May 24, 2000Date of Patent: April 9, 2002Assignee: Urocor, Inc.Inventors: Gang An, Robert Veltri
-
Patent number: 6218529Abstract: Disclosed are diagnostic techniques for the detection of human prostate, bladder and breast cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate, bladder and breast cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate, bladder and breast cancer compared to normal human prostate, benign prostatic hyperplasia, or normal bladder or breast tissue.Type: GrantFiled: June 12, 1998Date of Patent: April 17, 2001Assignee: UroCor, Inc.Inventors: Gang An, S. Mark O'Hara, David Ralph, Robert Veltri
-
Patent number: 6190857Abstract: Disclosed are diagnostic techniques for the detection of human disease states that affect gene expression in peripheral leukocytes. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. The invention further relates to methods for detection of protein species that are differentially expressed in the peripheral blood of individuals with such a disease state compared to normal healthy individuals. Genetic probes, antibody probes and methods useful in monitoring the progression and diagnosis of two specific disease states, prostatic cancer and breast cancer, are described.Type: GrantFiled: March 24, 1998Date of Patent: February 20, 2001Assignee: Urocor, Inc.Inventors: David Ralph, Gang An, S. Mark O'Hara, Robert Veltri
-
Patent number: 6171796Abstract: Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.Type: GrantFiled: August 3, 1999Date of Patent: January 9, 2001Assignee: Urocor, Inc.Inventors: Gang An, Robert W. Vertri
-
Patent number: 6156515Abstract: Disclosed are nucleic acid and amino acid sequences encoded by a novel, prostate specific gene (UC41) and diagnostic techniques for the detection of human prostate cancer utilizing such nucleic acid and amino acid sequences. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. Methods of treatment for prostate cancer utilizing antisense constructs or antibodies specific for UC41 gene products are also described.Type: GrantFiled: February 9, 1999Date of Patent: December 5, 2000Assignee: Urocor, Inc.Inventors: Gang An, Robert Veltri
-
Patent number: 6090559Abstract: Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.Type: GrantFiled: October 1, 1998Date of Patent: July 18, 2000Assignee: Urocor, Inc.Inventors: David W. Russell, Anice E. Thigpen
-
Patent number: 5989811Abstract: A method for screening individuals at risk for the loss of organ confinement in prostate cancer is disclosed. The method is useful for evaluating cells from patients at risk for recurrence of prostate cancer following surgery for prostate cancer. Specifically, the method uses specific Markovian nuclear texture features, alone or in combination with other biomarkers, to determine whether the cancer will progress or lose organ confinement. In addition, methods of predicting the development of fatal metastatic disease by statistical analysis of selected biomarkers is also disclosed. The invention also contemplates a method that uses a neural network to analyze and interpret cell morphology data. Utilizing Markovian factors and other biomarkers as parameters, the network is first trained with a sets of cell data from known progressors and known non-progressors. The trained network is then used to predict the loss of organ confinement by evaluating patient samples.Type: GrantFiled: September 29, 1995Date of Patent: November 23, 1999Assignee: Urocor, Inc.Inventors: Robert W. Veltri, M. Craig Miller, Michael P. Bacus, Kaveh Ashenayi
-
Patent number: 5972615Abstract: Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.Type: GrantFiled: January 21, 1998Date of Patent: October 26, 1999Assignee: Urocor, Inc.Inventors: Gang An, Robert W. Vertri
-
Patent number: 5882864Abstract: Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.Type: GrantFiled: July 31, 1996Date of Patent: March 16, 1999Assignee: Urocor Inc.Inventors: Gang An, S. Mark O'Hara, David Ralph, Robert Veltri
-
Patent number: 5861248Abstract: Disclosed are diagnostic techniques for the detection of human prostate cancer. Genetic probes and methods useful in monitoring the progression and diagnosis of prostate cancer are described. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in prostate cancer compared to normal human prostate or benign prostatic hyperplasia.Type: GrantFiled: March 29, 1996Date of Patent: January 19, 1999Assignee: Urocor, Inc.Inventors: David W. Russell, Anice E. Thigpen
-
Patent number: 5856112Abstract: A method for selectively inducing expression of biomarkers for urologic cancers, including prostate and bladder cancer, is disclosed. Tumor cells are cultured using a low shear rotational three-dimensional technique under conditions effective to induce said selective expression. The method is useful for diagnostic and therapeutic applications.Type: GrantFiled: June 16, 1994Date of Patent: January 5, 1999Assignee: UroCor, Inc.Inventors: Garry M. Marley, Robert W. Veltri